Tenax Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.03 Insider Own9.30% Shs Outstand25.26M Perf Week12.03%
Market Cap16.57M Forward P/E- EPS next Y-0.81 Insider Trans0.00% Shs Float16.59M Perf Month7.80%
Income-33.00M PEG- EPS next Q-0.16 Inst Own32.00% Short Float0.14% Perf Quarter-2.17%
Sales- P/S- EPS this Y-20.70% Inst Trans- Short Ratio0.62 Perf Half Y-49.92%
Book/sh0.17 P/B3.74 EPS next Y95.70% ROA-590.30% Target Price5.00 Perf Year-67.38%
Cash/sh0.21 P/C2.96 EPS next 5Y- ROE-822.00% 52W Range0.50 - 2.30 Perf YTD-38.85%
Dividend- P/FCF- EPS past 5Y44.80% ROI- 52W High-72.35% Beta2.04
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low27.17% ATR0.09
Employees8 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)49.10 Volatility13.54% 14.73%
OptionableNo Debt/Eq0.00 EPS Q/Q95.40% Profit Margin- Rel Volume0.27 Prev Close0.68
ShortableYes LT Debt/Eq0.00 EarningsMar 31 BMO Payout- Avg Volume36.71K Price0.64
Recom2.00 SMA200.23% SMA50-4.81% SMA200-41.19% Volume9,930 Change-6.44%
May-18-17Upgrade Ladenburg Thalmann Neutral → Buy
Dec-16-14Initiated MLV & Co Buy $7
Nov-18-14Initiated WallachBeth Buy $12
May-19-22 08:18AM  
May-18-22 08:30AM  
Apr-01-22 09:25AM  
Mar-31-22 08:30AM  
Mar-30-22 05:00PM  
Jan-31-22 04:10PM  
Jan-12-22 08:30AM  
Jan-05-22 11:48AM  
Jan-04-22 08:30AM  
Nov-18-21 11:54AM  
Nov-16-21 08:30AM  
Oct-06-21 08:30AM  
Sep-28-21 08:30AM  
Sep-20-21 10:43AM  
Sep-09-21 08:00AM  
Aug-17-21 08:00AM  
Aug-12-21 08:00AM  
Aug-05-21 08:00AM  
Jul-16-21 12:40PM  
Jul-07-21 08:00AM  
Jun-14-21 04:25PM  
Jun-10-21 08:30AM  
Jun-07-21 04:52PM  
May-17-21 05:15PM  
Apr-14-21 07:45AM  
Apr-09-21 11:38AM  
Apr-07-21 04:45PM  
Mar-31-21 04:45PM  
Mar-04-21 08:30AM  
Mar-02-21 08:15AM  
Jan-20-21 10:30AM  
Jan-19-21 07:45AM  
Dec-29-20 04:29PM  
Dec-03-20 07:47AM  
Nov-29-20 07:28PM  
Nov-16-20 04:45PM  
Nov-10-20 08:30AM  
Nov-06-20 08:30AM  
Oct-15-20 08:30AM  
Oct-02-20 08:30AM  
Sep-01-20 10:44AM  
Aug-31-20 08:30AM  
Aug-28-20 10:54AM  
Aug-17-20 08:00AM  
Jul-20-20 08:45AM  
Jul-06-20 07:50PM  
Jun-03-20 09:41AM  
Jun-02-20 07:30AM  
Jun-01-20 05:30AM  
May-29-20 01:07PM  
Apr-13-20 05:55AM  
Apr-09-20 08:30AM  
Mar-19-20 10:16AM  
Mar-12-20 08:30AM  
Feb-21-20 08:30AM  
Jan-21-20 06:15AM  
Jan-13-20 08:30AM  
Dec-20-19 12:03PM  
Nov-04-19 10:45AM  
Oct-31-19 08:00AM  
Sep-20-19 03:11PM  
Sep-12-19 09:15AM  
Aug-29-19 08:00AM  
Aug-23-19 08:00AM  
Jul-16-19 12:23PM  
Jun-12-19 11:25AM  
Apr-11-19 10:15AM  
Mar-11-19 03:20PM  
Feb-21-19 01:35PM  
Feb-04-19 08:30AM  
Jan-04-19 08:30AM  
Dec-11-18 04:00PM  
Dec-07-18 01:02PM  
Nov-26-18 11:00AM  
Nov-21-18 03:21PM  
Nov-19-18 08:00AM  
Nov-07-18 04:20PM  
Oct-01-18 09:04AM  
Sep-20-18 08:30AM  
Sep-04-18 10:45AM  
Aug-29-18 08:30AM  
Aug-28-18 08:30AM  
Jun-11-18 07:24PM  
Jun-07-18 09:30AM  
Jun-05-18 04:30PM  
Jun-04-18 08:37AM  
Jun-01-18 08:30AM  
May-24-18 02:27PM  
Apr-13-18 12:55PM  
Apr-12-18 10:10AM  
Apr-06-18 01:36PM  
Apr-05-18 02:43PM  
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.